Filibuvir

Summary

Filibuvir (CHEMBL490672) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including hepatitis c virus infection and chronic hepatitis c virus infection.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL490672
Name	Filibuvir
Type	Small molecule
Max phase	3

Also known as: Filibuvir, PF-00868554, PF-868554, filibuvir, FILIBUVIR

Patent coverage: 132 distinct patent families (307 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hepatitis C virus infection	2	MONDO:0005231	EFO:0003047
chronic hepatitis C virus infection	1	MONDO:0005354	EFO:0004220

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE1	4
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00720434	PHASE2	COMPLETED	A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection
NCT00987337	PHASE2	COMPLETED	Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects
NCT00445315	PHASE1	COMPLETED	A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients
NCT00651027	PHASE1	COMPLETED	Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554
NCT00918476	PHASE1	COMPLETED	Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol)
NCT01210404	PHASE1	COMPLETED	Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).